| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6121392 | Journal of Clinical Virology | 2011 | 4 Pages |
Abstract
The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Stephanie Gaillard, Jason B. Dinoso, Julia A. Marsh, Amy E. DeZern, Karen A. O'Connell, Adam M. Spivak, Karla Alwood, Christine M. Durand, Richard F. Ambinder, Joel N. Blankson,